Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Potenza Therapeutics

Roche - Basel

Roche re-joins UK pharma’s trade body the ABPI

Firm left in 2009 following its suspension for a major Code of Practice breach 

Novartis building

Anxiety over CAR-T follows Novartis closure of cell therapy unit

Firm maintains lead ALL project still on course for 2017 filings despite restructuring

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?

Blue Latitude Health

Products as portfolios: positioning immuno-oncology products

The last few years have seen a huge proliferation in the number of products entering the oncology space, with a lot more currently being investigated in clinical trials. Effective positioning...

Blue Latitude Health

Astellas launches digital health investment company

Will look for firms that focus on patient outcomes and offer pharma synergies

- PMLiVE

AstraZeneca embarks on oncology research access project

Invites companies to join molecular data resource consortium

Immunotherapy in oncology

Consultant David Cooney explores the medical insights, unmet needs, and future of the vastly growing area of immunotherapy as the fourth pillar in oncology.

Blue Latitude Health

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

- PMLiVE

Immunotherapy and future directions in oncology

How the field of cancer drugs is expanding as technology improves

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

- PMLiVE

Fertility drugs drive healthcare growth at Merck KGaA

Strong performances from Gonal-f and Rebif boost the firm’s 2016 sales forecast

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links